Financing Innovation - Early-stage companies are finding alternatives to venture capital. - BioPharm International

ADVERTISEMENT

Financing Innovation
Early-stage companies are finding alternatives to venture capital.


BioPharm International
Volume 26, Issue 4, pp. 24-26

TOUCHED BY AN ANGEL

One source of capital of increasing importance to early-stage life-sciences companies is angel capital. Jeffrey Sohl, director at the University of New Hampshire's (UNH) Center for Venture Research, notes that since 2007, the venture universe has seen an enormous "culling of the forest" as the number of active venture capitalists has shrunk to approximately 400 from 1200. That, along with the hesitance of the remaining firms to invest in early-stage life-sciences companies, has left a substantial funding gap that is being addressed by syndicates of angel investors. Angel investment in healthcare, biotechnology, and medical devices and equipment startups accounted for 36% of total angel investments in the first half of 2012, according to UNH Center for Venture Research.

Avaxia Biologics secured $6.4 billion from an angel syndicate in a series B financing in December 2012 to fund a first-in-human trial of its oral anti-TNF antibody, AVX-470, to treat ulcerative colitis for which it had just received FDA clearance. The drug is designed to act in the gastrointestinal tract to suppress inflammation and treat inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. Current anti-TNF antibodies work well but they are injected and suppress the entire immune system, which can lead to serious side effects. Avaxia's funding round was led by existing investor Cherrystone Angels and new investor Golden Seeds, with participation by nine other angel groups, many of whom are new investors attracted by the potential of its platform and its ability to localize treatment.

Angel investors in the US have organizations such as the Angel Capital Association that support their activities. Now, the idea has caught hold in the United Kingdom. Angels for Life Sciences launched in October 2012 as the first national angel network focused on helping raise money for early-stage life-sciences companies.

THE GEOGRAPHY OF VALUE

Another way that companies are accessing capital is by turning to opportunities to secure funding in countries that are trying to build their life-sciences sectors. Life-sciences companies, such as CompanDX, are finding that the value of their technology can vary by geography, and what may have marginal value in a developed market where healthcare providers have many competing choices, may have much greater value in emerging markets with unmet needs that are hungry for new technologies.

In July 2012, CompanDX, a UK diagnostics startup, raised $6.1 million (39.6 million RMB) from the Chinese government and private investors to develop and commercialize its products in China. The investment is nondilutive. Instead of taking an equity stake in the startup, investors will be eligible for a percentage of any revenue from commercialized products sold in China. CompanDX applies proprietary bioinformatics technology to advance personalized medicine. The company said that the Chinese investment would speed up its product development because of the regulatory climate in China and the willingness of major regional science parks there to provide funding for accelerated development for products relevant to the Chinese marketplace.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here